Effective and durable repigmentation for stable vitiligo: A randomized within-subject controlled trial assessing treatment with autologous skin cell suspension transplantation.
J Am Acad Dermatol
; 2024 Sep 07.
Article
en En
| MEDLINE
| ID: mdl-39182674
ABSTRACT
BACKGROUND:
Vitiligo lesions are often challenging to repigment with conventional medical therapies. Surgical autologous melanocyte transfer methods can be utilized for stable vitiligo but demand specialized skills and equipment. A point-of-care autologous cell harvesting device was designed enabling simple preparation of autologous skin cell suspension (ASCS) containing melanocytes, keratinocytes, and fibroblasts providing a straightforward approach for cellular transplantation.OBJECTIVE:
To evaluate the safety and effectiveness of ASCS for repigmentation of stable vitiligo lesions among adults.METHODS:
A US multicenter, randomized, within-subject controlled trial compared ASCS to narrow band ultraviolet B only (Control) in similar vitiligo lesions. ASCS was applied after laser skin resurfacing and followed by narrow band ultraviolet B treatment. The primary effectiveness endpoint was the proportion of lesions achieving ≥80% repigmentation at week-24. Repigmentation durability was assessed at week-52.RESULTS:
Among 25 subjects, 36% of ASCS-treated lesions achieved ≥80% repigmentation at week-24 compared to 0% for Control (P < .025), with durability through week-52. The safety profile of ASCS was acceptable, with favorable patient- and investigator-reported outcomes.LIMITATIONS:
Study sample size limited robust subgroup analyses.CONCLUSION:
Application of ASCS has potential as a treatment for repigmentation of stable vitiligo lesions with the potential to improve health-related quality of life and reduce burden of disease.
Texto completo:
1
Base de datos:
MEDLINE
Idioma:
En
Revista:
J Am Acad Dermatol
Año:
2024
Tipo del documento:
Article